Biostage (OTCMKTS:BSTG) announced its quarterly earnings data on Tuesday. The company reported ($0.37) earnings per share for the quarter, Bloomberg Earnings reports.
Shares of BSTG remained flat at $$2.33 during mid-day trading on Wednesday. 202 shares of the stock were exchanged, compared to its average volume of 2,913. The firm’s 50 day simple moving average is $2.25. Biostage has a 1 year low of $0.75 and a 1 year high of $3.75. The company has a current ratio of 1.81, a quick ratio of 1.81 and a debt-to-equity ratio of 0.03.
Separately, ValuEngine upgraded shares of Biostage from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.
Biostage, Inc, a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants. It is developing bioengineered organ implants, which addresses the damage of the esophagus, bronchus, and trachea due to cancer, infection, trauma, or congenital abnormalities.
Read More: Why do analysts give a neutral rating?
Receive News & Ratings for Biostage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostage and related companies with MarketBeat.com's FREE daily email newsletter.